ALACHUA, Fla.–(BUSINESS WIRE)–CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced a new collaboration with the Chattanooga Center for Neurologic Research (CCNR) based in Chattanooga, TN. CCNR is a biomedical research company led by globally recognized vascular neurologist Thomas G. Devlin, MD, PhD. In close partnership with Erlanger Health System and the University of Tennessee College of Medicine, Dr. Devlin has spearheaded the launch of various biotechnology companies whose commercialized products are having widespread impact on neurologic disease.
The collaboration is expected to lead to selection of CCNR and the Erlanger Health System as a site in CTD’s clinical trial in Alzheimer’s Disease, now in the design stage. As a first step in the collaboration, CCNR and CTD representatives will exchange confidential information on priority scientific topics and clinical capacity.
CTD Chairman and CEO N. Scott Fine said, “Given the significant overlap between stroke, dementia, and Alzheimer’s disease, we are delighted to undertake this collaboration with Dr. Devlin and his team as we build our respective Alzheimer’s programs. Dr. Devlin’s expertise as a world-class clinical researcher in neurovascular disease and stroke is directly applicable as we build out the CTD Alzheimer’s platform.”
Alzheimer’s Disease affects 5.7 million Americans. The disease takes an enormous toll on affected individuals, families and communities as loss of memory and ability to manage daily functions worsens. There are no approved disease modifying treatments. Physicians prescribe treatments for symptoms associated with the disease: these are not effective in all individuals.
Dr. Devlin said, “Tennessee is part of what’s known as the ‘stroke belt’ in the United States, with a stroke risk over 30% higher than other areas. We have turned this huge medical liability for our patients into a tremendous opportunity to partner with the best biomedical companies worldwide to spearhead new treatments. With Tennessee having the second highest death rate from Alzheimer’s disease of any state in the United States, we are now totally committed to continuing to identify visionary and innovative industry partners to align with as we launch our next major research initiative – Alzheimer’s disease. CTD Holdings is the perfect partner and I anticipate years of close and productive collaboration in our quest to cure Alzheimer’s.”
CTD Chief Scientific Officer Sharon Hrynkow, PhD stated, “Our proprietary cyclodextrin product, Trappsol® Cyclo™, which has an affinity for cholesterol, has shown encouraging findings in a single late-onset Alzheimer’s patient who has used it through an FDA-approved expanded access program for more than one year (see ClinicalTrials.gov NCT03624842). We are excited about the collaboration with Dr. Devlin and his CCNR team as we work to develop new knowledge about our drug’s potential benefit to Alzheimer’s patients.”
About CTD Holdings:
CTD Holdings, Inc. is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is in three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (Clinical Trials.gov NCT02939547, NCT02912793 and NCT03893071) and in an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development. For additional information, visit the company’s website: www.cyclotherapeutics.com
Safe Harbor Statement:
This press release contains “forward-looking statements” about the company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the company’s future performance include the company’s ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the company’s biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
RedChip Companies, Inc.